Simoa Accelerator Laboratory

 

Simoa Accelerator Laboratory

GREATER DEPTHS OF CONTRACT RESEARCH AT YOUR REACH

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The Simoa Accelerator Laboratory is a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. Our state-of-the-art facility includes a CLIA-certified lab and puts the power of groundbreaking Simoa technology to work to achieve research objectives for over 160 pharma and academic customers from all over the globe. As the innovators of the Simoa platform, the Accelerator Laboratory has completed more than 400 Simoa projects and well over 100,000 samples run to date – more than any other lab in the world. 

Quanterix’ team of dedicated scientists offer the greatest depth of instrument experience and ultra-sensitive assay development - all the way through manufacturing - giving you instant access to Simoa technology.  From expert and rapid development of custom assay kits, to selection of best antibody pairs, to running sample sets of any size, The Simoa Accelerator Lab treats every project with individualized attention to help your organization achieve its research and development goals efficiently and cost-effectively.

DOWNLOAD THE BROCHURE

The Simoa Accelerator Laboratory:

  • CLIA-Certified Laboratory
  • Offers the technology for single-plex and multiplex detection of proteins and nucleic acids, at ultra-sensitive levels
  • Provides the ability to use your proprietary antibodies/reagents or one of our extensive range of commercially-available assays
  • Infrastructure allows scalability to handle sample sets from one plate to thousands of samples
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope 
  • Onsite assay development training available through a comprehensive, 4-day program

Leverage Simoa for PK/PD, Efficacy, Safety and Target Engagement with the Highest Possible Sensitivity.

Already working with our Accelerator team? Follow this link to submit the Accelerator Project Form

Request to Learn More

Simoa Accelerator Leadership Team

Mark Roskey, Ph.D.
Senior Vice President, Commercial & Assays

Mark joined Quanterix in mid 2014 as the Vice President and General Manager of Applications and Reagents. He has more than 25 years of experience in the life science industry focusing on product R&D, applications development, strategic sales and marketing, and overall business management for complex biological solutions and automated instrument systems. He comes to Quanterix from PerkinElmer’s LST division where he was VP/GM of the America's Sales and Service organization. Prior to PerkinElmer, Mark held senior level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011. Mark holds a Ph.D. in Microbiology from the University of Notre Dame and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.

David Hanlon, Ph.D.
Vice President, Strategic Collaborations

Dr. Hanlon joined Quanterix in 2008 and oversees the Accelerator Laboratory, a service business dedicated to clinical sample testing and the development of novel assays utilizing the company’s single molecule array (Simoa) technology. Since its launch in 2014, the lab has expanded its capabilities to enable testing of up to 4,000 samples per day, and has completed over 400 projects from 145 organizations across the world. Prior to Quanterix, Dr. Hanlon led several external research collaborations at Cytyc (Hologic) to discover novel biomarkers of cervical neoplasia, as well as an internal team focused on marker validation and the development of diagnostic assays. Dr. Hanlon was Director, R&D at VisEn Medical and Project Manager at Proteome (Incyte), where he led a team of scientists developing protein-centric databases for comparative and functional genomic applications. He also served as Director of Neuroscience at Oncogene Research Products where he developed a life science portfolio consisting of neurochemical and immunological products. Dr. Hanlon received his Ph.D. from the University of Illinois, Urbana-Champaign and was a postdoctoral research fellow at Harvard University and the University of California, San Diego. He obtained a B.S. degree in Biochemistry from Worcester Polytechnic Institute.

Dan Sikkema, Ph.D.
Dan Sikkema, Ph.D.
Vice President, Accelerator and Pharma Services

Dr. Dan Sikkema brings 25 years’ experience in the biopharmaceutical, vaccine and cell/gene therapy fields supporting oncology, neurosciences, respiratory, immunology and infectious disease, plus 10 years in diagnostic medicine in CLIA laboratories. Prior to joining Quanterix, Dan held positions of increasing responsibility at Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, Frontage Laboratories and GlaxoSmithKline. In his career, he has contributed to the licensure of biopharmaceuticals including Prev(e)nar, Meningitec, Gardasil, RotaTeq, ProQuad and Zostavax, Ofatumumab, Raxibacumab, Benlysta, Albiglutide, Mepolizumab, Denosumab, and Strimvelis. Dan has also worked with the World Health Organization, National Institute for Biological Standards and Controls (NIBSC), US Centers for Disease Control, FDA, and EMA as an invited expert and advisor. Dr. Sikkema holds a PhD in Microbiology and Public Health from Michigan State University, College of Medicine and served as both a Post-Doctoral Fellow and a Research Assistant Professor in Infectious Diseases at SUNY at Buffalo, School of Medicine. Additionally, Dan is a Registered Medical Technologist with the American Society for Clinical Pathologists and is a former Chairman of Division V for American Society for Microbiology and Coordinator for an Innovative Medicine Initiative project ABIRISK, the largest funded project to study Immunogenicity of Biotherapeutics. Dr. Sikkema has authored 30 peer-reviewed publications and delivered over 75 public presentations globally at scientific symposia.

Simoa Accelerator Lab by the Numbers

Customers to Date
Projects to Date
Samples Run to Date